Latest news and press releases about MiNK Therapeutics, Inc. (INKT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction.
Price
| Price | $11.59 |
| Market Cap | $58M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -4.08 |
| EV / EBITDA | -4.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 83.45% |
| Return on Invested Capital | -604.20% |
| Return on Assets | -118.15% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CRVO · EQ · GANX · HOWL · IOBT · NRXP · OSTX
Explore sector: Healthcare · Biotechnology
More sections of INKT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks